Key Points
- Director Lewis Titterton Jr. bought 49,036 Anixa Biosciences shares at an average price of $2.69, investing approximately $131,907 and increasing his ownership by 4.92% to 1.046 million shares.
- Anixa’s stock opened at $2.78, with a market capitalization of about $96.6 million; shares have traded between $2.32 and $5.46 over the past year. The company met quarterly earnings expectations with a loss of $0.08 per share.
- Analyst sentiment is mixed, with three Buy ratings, one Hold, and one Sell, resulting in an overall “Hold” rating and an average price target of $8.00.
Anixa Biosciences Inc (NASDAQ:ANIX - Get Free Report) Director Lewis Titterton, Jr. purchased 49,036 shares of the firm's stock in a transaction that occurred on Wednesday, September 23rd. The shares were acquired at an average price of $2.69 per share, with a total value of $131,906.84. Following the purchase, the director owned 1,046,003 shares in the company, valued at $2,813,748.07. This trade represents a 4.92% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Anixa Biosciences Stock Performance
Shares of Anixa Biosciences stock opened at $2.78 on Friday. The company has a market capitalization of $96.63 million, a P/E ratio of -8.69 and a beta of 0.51. Anixa Biosciences Inc has a 1 year low of $2.32 and a 1 year high of $5.46. The company's fifty day moving average is $3.24 and its two-hundred day moving average is $2.97.
Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last announced its earnings results on Wednesday, September 9th. The company reported ($0.08) EPS for the quarter, meeting analysts' consensus estimates of ($0.08). As a group, equities analysts expect that Anixa Biosciences Inc will post -0.31 earnings per share for the current year.
Institutional Trading of Anixa Biosciences
Large investors have recently bought and sold shares of the company. Sanctuary Advisors LLC purchased a new position in shares of Anixa Biosciences in the second quarter valued at $29,000. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Anixa Biosciences in the 2nd quarter worth about $29,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Anixa Biosciences in the 2nd quarter worth about $30,000. Simplicity Wealth LLC acquired a new stake in Anixa Biosciences in the 2nd quarter valued at about $34,000. Finally, NewEdge Wealth LLC acquired a new stake in Anixa Biosciences in the 2nd quarter valued at about $35,000. Institutional investors and hedge funds own 29.13% of the company's stock.
Analyst Ratings Changes
Several research firms have commented on ANIX. Weiss Ratings raised Anixa Biosciences from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, September 17th. Zacks Research downgraded Anixa Biosciences from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 19th. D. Boral Capital reissued a "buy" rating and issued a $10.00 target price on shares of Anixa Biosciences in a report on Tuesday, June 30th. Wall Street Zen upgraded Anixa Biosciences from a "sell" rating to a "hold" rating in a research note on Saturday, June 20th. Finally, HC Wainwright decreased their price target on Anixa Biosciences from $7.00 to $6.00 and set a "buy" rating for the company in a report on Tuesday. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Anixa Biosciences presently has an average rating of "Hold" and an average price target of $8.00.
Read Our Latest Stock Report on Anixa Biosciences
About Anixa Biosciences
(
Get Free Report)
Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases. The company's research programs are designed to use the immune system to prevent or treat serious illnesses.
Anixa's cancer programs include vaccine approaches for ovarian cancer and triple-negative breast cancer, developed in collaboration with researchers at Cleveland Clinic. The company is also developing chimeric antigen receptor T-cell, or CAR-T, therapies intended to target cancer cells, including programs focused on ovarian cancer.
In addition to oncology, Anixa has pursued vaccine and therapeutic technologies for infectious diseases.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
